FDA group model in R [Two-Stage / GS Designs]

posted by VStus – Poland, 2016-10-20 15:57 (3522 d 12:27 ago) – Posting: # 16745
Views: 44,833

Dear Maestro,

❝ I actually lost a bit track of this discussion and I am not exactly sure what the comparisons try to achieve?!?


I'm sorry for confusion. I accept that I for sure may understood this topic completely wrong. I just wanted to address Myttiry's issue of non-similar results between R's lm() and WinNonlin in assessment of the FDA group model 1 and 2 for unbalanced dataset.

I don't have access to SAS or WinNonlin, but I have some study reports assessed via SAS using FDA's group model 1 and 2. So, in regards to Point Estimates, 90% CIs, F and P values for:
FDA Group 1 Group*Treat #Treat:Group in my R output
FDA Group 2
- Treat #Drug in my R output
- Per(Group) # group:prd in my R output
- Subj(Group*Seq) # seq:subj in R
lm() provides same results as PROC GLM

If Russian Authorities require an additional assessment using a group model, R output should be ok. So as PHX, if PE and 90%CI are not calculated using FDA Group Model 1.

Regards,
VStus

Complete thread:

UA Flag
Activity
 Admin contact
23,653 posts in 4,991 threads, 1,571 registered users;
111 visitors (0 registered, 111 guests [including 20 identified bots]).
Forum time: 04:24 CEST (Europe/Vienna)

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5